1
/
of
1
Dapazox (Dapagliflozin)
Dapazox (Dapagliflozin)
Regular price
₱1,395.00 PHP
Regular price
Sale price
₱1,395.00 PHP
Unit price
₱46.50 each
Taxes included.
Quantity
Couldn't load pickup availability
Dapazox (Dapagliflozin) is a prescription SGLT2 inhibitor medication designed to improve glycemic control and provide comprehensive cardiovascular and renal protection for adults with type 2 diabetes. By blocking the SGLT2 transporter in the kidneys, dapagliflozin promotes urinary glucose excretion, effectively lowering blood glucose levels while supporting modest weight loss and reduced blood pressure.
Beyond diabetes management, dapazox has emerged as a cornerstone therapy for heart failure with both reduced and preserved ejection fraction, as well as for chronic kidney disease regardless of diabetes status. Clinical evidence demonstrates that dapagliflozin significantly reduces hospitalizations related to heart failure, slows the progression of kidney disease, and improves long-term patient outcomes. This versatility makes it a preferred choice across modern diabetes, cardiovascular, and chronic kidney disease treatment guidelines.
Dapagliflozin offers distinct pharmacological advantages including once-daily convenient dosing, weight neutrality compared to alternative treatments, and a remarkably low hypoglycemia risk profile. These characteristics have made dapazox a widely recommended medication for patients requiring multifaceted protection across metabolic and cardiovascular domains. The medication works by blocking kidney proteins that normally reabsorb glucose back into the bloodstream, forcing the body to eliminate excess sugar through urinary excretion. This mechanism provides both immediate glycemic benefits and sustained organ protection.
The standard adult dose is 10 mg taken orally once daily, with flexible administration that allows patients to take the medication with or without food. Dapazox represents an important therapeutic option for managing complex patient populations with overlapping conditions requiring integrated cardiovascular, renal, and metabolic protection.
Beyond diabetes management, dapazox has emerged as a cornerstone therapy for heart failure with both reduced and preserved ejection fraction, as well as for chronic kidney disease regardless of diabetes status. Clinical evidence demonstrates that dapagliflozin significantly reduces hospitalizations related to heart failure, slows the progression of kidney disease, and improves long-term patient outcomes. This versatility makes it a preferred choice across modern diabetes, cardiovascular, and chronic kidney disease treatment guidelines.
Dapagliflozin offers distinct pharmacological advantages including once-daily convenient dosing, weight neutrality compared to alternative treatments, and a remarkably low hypoglycemia risk profile. These characteristics have made dapazox a widely recommended medication for patients requiring multifaceted protection across metabolic and cardiovascular domains. The medication works by blocking kidney proteins that normally reabsorb glucose back into the bloodstream, forcing the body to eliminate excess sugar through urinary excretion. This mechanism provides both immediate glycemic benefits and sustained organ protection.
The standard adult dose is 10 mg taken orally once daily, with flexible administration that allows patients to take the medication with or without food. Dapazox represents an important therapeutic option for managing complex patient populations with overlapping conditions requiring integrated cardiovascular, renal, and metabolic protection.
Share
